NBC Securities Inc. Sells 1,893 Shares of Johnson & Johnson $JNJ

Key Points

• NBC Securities Inc. has reduced its stake in Johnson & Johnson by 4.6%, selling 1,893 shares to hold a total of 39,345 shares valued at approximately $6 million.
• Several institutional investors, including Apella Capital LLC and Boltwood Capital Management, have increased their holdings in Johnson & Johnson, indicating ongoing confidence in the stock.
• The company recently reported earnings of $2.77 per share for the quarter, above analysts' estimates, and announced a quarterly dividend of $1.30 per share, reflecting a yield of 2.9%.

NBC Securities Inc. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 39,345 shares of the company's stock after selling 1,893 shares during the quarter. Johnson & Johnson makes up about 0.5% of NBC Securities Inc.'s investment portfolio, making the stock its 24th biggest position. NBC Securities Inc.'s holdings in Johnson & Johnson were worth $6,009,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Highline Wealth Partners LLC grew its stake in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new stake in Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter worth approximately $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the first quarter worth approximately $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in shares of Johnson & Johnson during the first quarter worth approximately $52,000. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Down 0.3%

NYSE JNJ traded down $0.57 during trading hours on Monday, hitting $177.49. The company's stock had a trading volume of 4,767,621 shares, compared to its average volume of 7,435,351. The stock has a fifty day moving average of $171.25 and a 200 day moving average of $161.36. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The firm has a market capitalization of $427.46 billion, a P/E ratio of 18.98, a PEG ratio of 2.27 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period in the prior year, the business posted $2.82 earnings per share. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on JNJ shares. UBS Group upped their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Citigroup upped their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday, August 21st. Barclays upped their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Morgan Stanley upped their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Finally, Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.